ChemPartner has worked with hundreds of global biopharmaceutical companies by establishing, optimizing and running hundreds of assays, screening millions of compounds and generating millions of data points for our research partners. Our staff is led by senior scientists with rich international drug discovery experience, enabling the generation of rapid, high-quality data that our partners require for their programs.
Our Assay Technology Team implements new technology to develop, optimize and validate a large variety of assays on GPCRs, kinases, NHRs, metabolic enzymes, epigenetic enzymes, ligand-gated ion channels, and transporters. This team focuses on executing HTS campaigns for our clients.
We apply state-of-the-art technologies including FLIPR, HTRF, alpha screen, radiometry, FACS, LC/MS, and nanoliter liquid handling to the assays, and we continually expand and deepen our capabilities. We have recently added full HTS automation and label-free technology into our high technology in order to align ourselves with the full specifications and needs of our pharma partners. Robust assay data reproducibility, problem-solving skills, adaptability to clients’ research needs are some of the unique strengths of ChemPartner.
Our Drug Discovery Team works closely with chemistry, biology, pharmacology, ADME/PK/PD and toxicology colleagues in collaborative project teams, discovering and advancing compounds, for our pharma and biotech partners from Hit-to-Lead, Lead-Optimization, and early-stage development programs. ChemPartner is committed to conducting research with the same scientific rigor and sense of urgency as our biopharmaceutical partners.